Response Genetics' Q2 Revenues Nearly Triple | GenomeWeb

NEW YORK (GenomeWeb News) – Response Genetics today reported that its second-quarter revenues nearly tripled, due to sales of the firm's ResponseDx genetic tests.

The Los Angeles-based firm reported total revenues of $5.6 million for the three-month period ended June 30, compared to $1.9 million for the second quarter of 2009. It said that sales of its ResponseDx tests increased 687 percent to $3.5 million for the quarter from $446,000 for Q2 2009.

Response Genetics also trimmed its net loss to $425,038, or $.02 per share, from $2.4 million, or $.19 per share.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.